Today is the World Health Day and the theme for this year is the Diabetes.
We are glad to say that Asphalion contributes to the development of a new therapy to treat
Diabetes in a project called ELASTISLET conducted by several European
institutions and companies. ELASTISLET is funded by the European Commission
under the Horizon 2020 Programme.
Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose
which directly impacts millions of people globally, and its prevalence has
steadily increased in the past few decades.
Diabetes is a noncommunicable disease (NCD) directly impacting millions of people of
globally, mostly in low- and middle-income countries. Diabetes is a chronic,
metabolic disease characterized by elevated levels of blood glucose which may
over time lead to serious damage to the heart, blood vessels, eyes, kidneys,
and nerves. The prevalence of diabetes has been steadily increasing in the past
few decades, in particular in low- and middle-income countries. Knowledge
exists to reverse this trend through targeted prevention and appropriate care.
World Health Organitzation: http://www.who.int/en/
Asphalion is currently working in ELASTISLET project. The general objective of this
project is the development of immunoisolation and scaffolding systems based on
multibiofunctional elastin-like recombinamers (ELRs) for long-term and
efficient pancreatic islet and human induced pluripotential stem cells (hiPSCs)
transplantation for Diabetes Mellitus (DM) treatment. These encapsulating
materials will be tailor-designed as a multi-strategy and cross-disciplinary
approach addressing the challenges appearing both at the implant-surrounding
tissue interface and to the cell/islet-biomaterial inner interface. This
project is developed thorught the European Comission for Horizon 2020